DOAJ Open Access 2022

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma

Dongmei Zhang Yunzhen Zhou Yanan Ma Ping Jiang Hongchao Lv +11 lainnya

Abstrak

Abstract Precision medicine in hepatocellular carcinoma (HCC) relies on validated biomarkers that help subgroup patients for targeted treatment. Here, we identified a novel candidate oncogene, ribosomal protein L22-like1 (RPL22L1), which was markedly elevated in HCC, contributed to HCC malignancy and adverse patient survival. Functional studies indicated RPL22L1 overexpression accelerated cell proliferation, migration, invasion and sorafenib resistance. Mechanism studies revealed that RPL22L1 activated ERK to induce atypical epithelial-to-mesenchymal transition (EMT) progress. Importantly, the ERK inhibitor (ERKi) could potentiate sorafenib efficiency in RPL22L1-high HCC cells. In summary, these data uncover RPL22L1 is a potential marker to guide precision therapy for utilizing ERKi to enhance the sorafenib efficacy in RPL22L1-high HCC patients.

Topik & Kata Kunci

Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cytology

Penulis (16)

Dongmei Zhang

Yunzhen Zhou

Yanan Ma

Ping Jiang

Hongchao Lv

Sijia Liu

Yu Mu

Chong Zhou

Shan Xiao

Guohua Ji

Peng Liu

Ning Zhang

Donglin Sun

Haiming Sun

Nan Wu

Yan Jin

Format Sitasi

APA MLA BibTeX

Zhang, D., Zhou, Y., Ma, Y., Jiang, P., Lv, H., Liu, S. et al. (2022). Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma. https://doi.org/10.1038/s41420-022-01153-8

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.1038/s41420-022-01153-8

Informasi Jurnal

Tahun Terbit: 2022
Sumber Database: DOAJ
DOI: 10.1038/s41420-022-01153-8
Akses: Open Access ✓